Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dennis Demont"'
Autor:
Maaike Emmelot, Dennis Demont, Edwin de Zwart, Allard Kaptein, Bas van de Kar, Saskia Verkaik, Tjeerd Barf, Niels Hoogenboom
Publikováno v:
Bioorganicmedicinal chemistry letters. 52
Epidermal growth factor receptor (EGFR) inhibitors have clinical utility in the treatment of non-small cell lung cancer (NSCLC) patients. Despite encouraging clinical efficacy with these agents, many patients develop resistance due to sensitizing (or
Autor:
Tjeerd Barf, Bart Van Lith, Todd Covey, Dennis Demont, Niels Hoogenboom, Bas van de Kar, Saskia Verkaik, Allard Kaptein, Maaike van Hoek, Gerjan de Bruin, Michael Gulrajani, Edwin de Zwart
Publikováno v:
Bioorganicmedicinal chemistry letters. 30(14)
Bruton tyrosine kinase (BTK) is an important target in oncology and (auto)immunity. Various BTK inhibitors have been approved or are currently in clinical development. A novel BTK inhibitor series was developed starting with a quinazoline core. Movin
Autor:
Dennis Demont, Roger G. Ulrich, Tjeerd Barf, Raquel Izumi, Allard Kaptein, Bart Van Lith, Edwin de Zwart, Michael Gulrajani, Todd Covey, Saskia Verkaik, Paul G. Pearson, Diana Mittag, Bas van de Kar, Fanny Krantz, Maaike van Hoek
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 363(2)
Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns. Herein we describe the pharmacologic characterization
Autor:
Diana Mittag, Bas van de Kar, Tjeerd Barf, Dennis Demont, Todd Covey, Anouk de Jong, Gerjan de Bruin, Maaike Emmelot-van Hoek, Allard Kaptein, Michael Gulrajani
Publikováno v:
Blood. 132:1871-1871
Background: Bruton tyrosine kinase (BTK) is a validated target for B-cell malignancies. The BTK inhibitor ibrutinib was approved in chronic lymphocytic leukemia, mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia. Acalabrutinib is a potent
Autor:
Judith Versteegh, Nicole Seegers, Henri Klop, Tjeerd Barf, Claudia Hofstra, Jeroen A.D.M. de Roos, Carsten Schultz-Fademrecht, Mario van Zeeland, Arthur Oubrie, Bert Kazemier, Maaike van Hoek, Dennis Demont, Allard Kaptein, Jorrit J. Hornberg, Sander de Wilde, Ruben L. Smeets, Bas van de Kar, Ruud van der Heijden, Richard van Someren
Publikováno v:
Bioorganic & Medicinal Chemistry Letters, 21, 3818-22
Bioorganic & Medicinal Chemistry Letters, 21, 12, pp. 3818-22
Bioorganic & Medicinal Chemistry Letters, 21, 12, pp. 3818-22
Item does not contain fulltext MK2 kinase is a promising drug discovery target for the treatment of inflammatory diseases. Here, we describe the discovery of novel MK2 inhibitors using X-ray crystallography and structure-based drug design. The lead h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bdeec28829a3848ff7f20ab076a3584
http://hdl.handle.net/2066/97376
http://hdl.handle.net/2066/97376
Autor:
Kaptein, Allard, de Bruin, Gerjan, Hoek, Maaike Emmelot-van, van de Kar, Bas, de Jong, Anouk, Gulrajani, Michael, Demont, Dennis, Covey, Todd, Mittag, Diana, Barf, Tjeerd
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia; 2019 Supplement 1, Vol. 19, pS316-S317, 2p